Loading…
TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
Upregulation of the telomerase reverse transcriptase ( ) gene in human cancers leads to telomerase activation, which contributes to the growth advantage and survival of tumor cells. Molecular mechanisms of upregulation are complex, tumor-specific and can be clinically relevant. To investigate these...
Saved in:
Published in: | Oncotarget 2017-09, Vol.8 (44), p.77540-77551 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Upregulation of the telomerase reverse transcriptase (
) gene in human cancers leads to telomerase activation, which contributes to the growth advantage and survival of tumor cells. Molecular mechanisms of
upregulation are complex, tumor-specific and can be clinically relevant. To investigate these mechanisms in breast cancer, we sequenced the
promoter, evaluated
copy number changes and assessed the expression of the
oncogene, a known transcriptional
regulator, in two breast cancer cohorts comprising a total of 122 patients. No activating
promoter mutations were found, suggesting that this mutational mechanism is not likely to be involved in
upregulation in breast cancer. The T349C promoter polymorphism found in up to 50% of cases was not correlated with
expression, but T349C carriers had significantly shorter disease-free survival.
gains (15-25% of cases) were strongly correlated with increased
mRNA expression and worse patient prognosis in terms of disease-free and overall survival. Particularly aggressive breast cancers were characterized by an association of
gains with
overexpression. These results evidence a significant effect of gene copy number gain on the level of
expression and provide a new insight into the clinical significance of
and
upregulation in breast cancer. |
---|---|
ISSN: | 1949-2553 1949-2553 |
DOI: | 10.18632/oncotarget.20560 |